INGENOX
LIVE

Serial Number

98015547

Owner

INGENOX THERAPEUTICS LIMITED

Attorney

Patrice P. Jean

Filing Date

May 26, 2023

Add to watchlist:

No watchlists yet
View on USPTO

INGENOX Trademark

Serial Number: 98015547 • Registration: 7437794

INGENOX is a trademark filed by INGENOX THERAPEUTICS LIMITED on May 26, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

INGENOX THERAPEUTICS LIMITED (2 trademarks)

Magdalen Centre Robert Robinson Avenue
Oxford OX44GA , GB

Entity Type: 99

Trademark Details

Filing Date

May 26, 2023

Registration Date

July 9, 2024

Published for Opposition

April 23, 2024

Goods & Services

Epigenetic drugs for the treatment, diagnosis, detection and/or prevention of cancer; epigenetic drugs targeting arginine methylation in cancer; inhibitors of arginine methylation for the treatment of cancer; inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; compounds for the treatment, diagnosis, detection and/or prevention of cancer; pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer

biochemical research and development services; medical research and development services; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and/or cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and/or prevention of cancer; consultancy, advisory and/or information services relating to or connected with the aforementioned services

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 9, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 9, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 23, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 23, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 3, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 13, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 13, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 13, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 13, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 13, 2024 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Mar 11, 2024 ZZZX
WITHDRAWN FROM PUB - OG REVIEW QUERY
Mar 5, 2024 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 20, 2024 CNSA
ASSIGNED TO EXAMINER
Feb 20, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 27, 2023 NWOS
NEW APPLICATION ENTERED
May 30, 2023 NWAP